Compare GAUZ & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAUZ | MBAI |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Miscellaneous | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 8.8M |
| IPO Year | 2019 | 2014 |
| Metric | GAUZ | MBAI |
|---|---|---|
| Price | $0.39 | $6.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $11.50 | N/A |
| AVG Volume (30 Days) | ★ 11.9M | 70.7K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.59 | N/A |
| Revenue Next Year | $59.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.95 |
| 52 Week High | $7.07 | $10.21 |
| Indicator | GAUZ | MBAI |
|---|---|---|
| Relative Strength Index (RSI) | 49.88 | 59.96 |
| Support Level | $0.36 | $1.19 |
| Resistance Level | $0.50 | $10.21 |
| Average True Range (ATR) | 0.06 | 0.44 |
| MACD | -0.00 | -0.28 |
| Stochastic Oscillator | 51.23 | 9.23 |
Gauzy Ltd is a fully integrated light and vision control company. Its products products include suspended particle device, or SPD, and liquid crystal, or LC, materials for smart glass applications, and AI-powered advanced driver assistance systems, or ADAS, solutions including camera monitoring systems, or CMS. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.